All Updates

All Updates

icon
Filter
Funding
Transition Bio raises USD 50 million in Series A
AI Drug Discovery
Jun 2, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Jun 2, 2022

Transition Bio raises USD 50 million in Series A

Funding

<ul><li> Massachusetts-based AI biotechnology company Transition Bio has raised USD 50 million in a Series A funding round led by Northpond Ventures, with participation from Bristol-Myers Squibb, Taiho Ventures, Magnetic Ventures, and other existing investors. The round follows the company’s seed round in November 2020. </ul>

  • The proceeds will be directed toward advancing its AI-powered drug discovery platform Condensomics and exploring a variety of therapeutic areas and disease indications. 

  • Founded in 2020, Transition Bio leverages AI, machine learning, and microfluidics to develop novel therapeutics based on biomolecular condensates—organelles inside cells that contribute to diseases. The company’s platform follows a four-tier approach: 1) PhaseScan, which screens and gathers data on condensate modulations; 2) CelPhase for imaging and analytics; 3) PhaseSeq to identify best condensate targets by analyzing its effect on cellular processes; and 4) DeePhase for target prediction and in-silico drug discovery.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.